Serojec

Drugs for Treating Premature Ejaculation

Health Tech & Life Sciences
Private

Company Overview

Snapshot

Founded in January 2019 by Dr. Daniel Drai, Serojec operates with 1–10 employees. The company is in the Pre-Funding stage and has completed a Phase I trial for its drug to treat premature ejaculation, conducted in cooperation with the University of Vienna.

Business overview

Serojec is a pharmaceutical company focused on developing drugs to treat premature ejaculation. The company's core technology involves combining existing drugs, specifically a tricyclic antidepressant in low dosage and an alkaloid that relaxes blood vessels. This combination aims to neutralize side effects while enhancing efficacy. Serojec serves the urology and broader pharmaceutical markets, operating within the Health Tech & Life Sciences sector, with a specific focus on drug discovery and development.

Strategic signal

In January 2020, Serojec announced the development of its drug to treat premature ejaculation. This signals the company's progress in addressing a significant medical need through a novel drug combination, indicating potential for market disruption in urological treatments and validating its research and development efforts.

Company Intelligence Q&A

What is Serojec's primary focus?
Serojec develops drugs to treat premature ejaculation by combining existing pharmaceutical compounds to enhance efficacy and mitigate side effects.
Who founded Serojec?
Serojec was founded by Dr. Daniel Drai in January 2019.
What is the current development stage of Serojec's drug?
Serojec has completed a Phase I trial to verify the safety and show signs of effectiveness for its drug, conducted in cooperation with the University of Vienna.
What is the key innovation in Serojec's drug development?
Serojec's innovation lies in combining a low-dosage tricyclic antidepressant with an alkaloid that relaxes blood vessels, where each drug neutralizes the other's side effects while treating premature ejaculation.
When did Serojec announce the development of its drug?
In January 2020, Serojec announced the development of its drug to treat premature ejaculation.